Actively Recruiting
Pilot Observational Study on the Impact of e-Bug Educational Programme on Parental Consent and HPV Vaccination Coverage During National School Vaccination Campaigns in Alpes-Maritimes Middle School
Led by Centre Hospitalier Universitaire de Nice · Updated on 2025-12-05
11000
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are assessing how an existing educational programme called e-Bug may influence parental consent and HPV vaccination rates among middle school students during the 2023-2024 and 2024-2025 national school vaccination campaigns in France. The study focuses on one middle school in the Alpes-Maritimes department where teachers and the school nurse have been trained on HPV and used e-Bug materials as part of routine health education. This observational pilot study does not introduce or change the education programme but uses existing vaccination data collected by the Regional Health Agency. The study compares aggregated and anonymized vaccination data from the pilot school with those from other middle schools in the Alpes-Maritimes department. No research-related interventions or individual participant recruitment occur. The analysis covers HPV vaccination uptake for both first and second doses, parental consent rates, and the return rate of vaccination authorization forms collected during the two-year vaccination campaigns. Data are collected routinely by the health agency and are analyzed in an aggregated form to understand if the educational approach is linked to increased parental acceptance and vaccination coverage. This study does not involve direct participant interaction or data collection beyond existing records. The observation period spans from the start of the 2023-2024 campaign through the end of the 2024-2025 campaign, with no additional follow-up required from schools or families.
CONDITIONS
Brief Title
Impact of an e-Bug Educational Intervention on HPV Vaccine Uptake in Middle School Students
Who Can Participate
Eligibility Criteria
You may qualify if you...
- No individual participants are enrolled. The study uses only aggregated, anonymised vaccination data routinely collected by ARS PACA
You will not qualify if you...
- Not applicable. No individual-level inclusion or exclusion criteria are defined, as no participants are enrolled.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
No individual visits; data are collected from routine vaccination records.
Duration - From the start of the 2023-2024 HPV vaccination campaign to the end of 2024-2025
Participants who undergo routine care are observed for HPV vaccination uptake and parental consent rates during the school vaccination campaigns.
Data collected continuously through routine vaccination authorisation form returns and vaccination records.
Trial Site Locations
Total: 1 location
1
CHU de NICE
Nice, Alpes Maritimes, France, 06000
Actively Recruiting
Research Team
L
Laure Hermet
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here